RU2734250C2 - Dental film for treating and preventing alveolitis with phytopeloid composition - Google Patents

Abstract

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a dental film for treating and preventing alveolitis. Dental film for treating and preventing alveolitis with herbal extract based phytopheloid composition which contains a dried aqueous extract of astragalus foxtail grass, essential oil of peppermint, aqueous extract of sulphide-silt iodine-bromine therapeutic mud, gelatine, glycerin, lidocaine hydrochloride, ascorbic acid, nipagin, sorbitol sweetener and purified water in certain proportions.

EFFECT: above described film is effective for treating and preventing alveolitis, convenient and hygienic in use, with good fixation and prolonged effect, has antimicrobial and antibacterial action.

1 cl, 2 tbl, 4 ex

Description

The invention relates to medicine and pharmacy, in particular to the development of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition.

One of the most widespread and common dental diseases is alveolitis, which often occurs after the extirpation (extraction) of teeth. Alveolitis, as a rule, develops in the postoperative period and is accompanied by infection of tissues located near the tooth socket.

In addition, trauma to the walls of the holes contributes to the occurrence of this disease, which is explained by their fine structure, which is prone to damage; in some cases, they are completely "broken out" during the extraction of teeth from the gum bone. This process is accompanied by the destruction of bone tissue, and their fragments enter the hole and lead to infection.

The risk factor for the development of alveolitis is the presence of infectious "agents" in the oral cavity, among which staphylococci and streptococci are the most common. In addition, caries is also a provoking factor, which often turns into periodontitis, pulpitis and periostitis, accompanied by a high risk of infection, which creates the problem of the complexity of creating sterile conditions during surgical intervention.

The spread of infection leads to the development of purulent inflammation, which initially affects the upper layers of the gums with a further transition to all tissues. After that, various complications may occur, the most common of which are: periostitis, abscess, phlegmon.

For the treatment of infectious and inflammatory diseases of the oral mucosa, drugs of various pharmacological groups are used, depending on the etiology and pathogenesis of the diseases. As a rule, these include a variety of antibacterial drugs (metronidazole, dioxidine), antibiotics (azithromycin, erythromycin, gramicidin), antiseptic drugs (chlorhexidine, hydrogen peroxide, rivanol, furacilin) [Ivanchenko I.G. Pharmacotherapy for periodontal diseases // Periodontology. 2001. - No. 1-2 (19-20). - S. 8.].

Known dental films "Diplen-Denta" "NORD-OST" (Moscow) of different compositions: with lincomycin, metronidazole, gentamycin, clindamycin, solcoseryl, fluorine and chlorhexidine, lidocaine and chlorhexidine, dexamethasone and chlorhexidine, teeth whitening with hydrogen peroxide. These films are easy to use, firmly fixed on the gums, thin, elastic, transparent.

However, with their pronounced therapeutic effect, they are not devoid of side effects, have contraindications and restrictions to the use of [DiplenDenta - dental self-adhesive film [Electronic resource] Access mode: http://dentashop.ru/diplen.html.].

It is known "Means for the treatment of inflammatory periodontal diseases" (RU 2376016 from 20.12.2009) in the form of a film for the treatment of inflammatory periodontal diseases based on gelatin, containing glycerin and water and as medicinal components: lincomycin, metronidazole, lidocaine and dexamethasone.

However, it is worth noting that with a pronounced therapeutic effect, antibacterial agents and, accordingly, antibiotics, in the presented composition, are not devoid of side effects, have contraindications and restrictions for use.

Thus, the development of complex approaches to the treatment of diseases of the oral cavity, including the use of herbal medicinal products, which would make it possible to limit the antibacterial load and ensure detoxification of the body, is relevant today.

Herbal medicines and preparations containing herbal ingredients have long been successfully used in dental practice. The preparations created on the basis of plant raw materials are characterized by a unique chemical composition, a wide spectrum of action, absence of toxicity and side effects, efficiency with prolonged use, availability according to the criteria of resource supply and renewability.

Traditionally, for the treatment of inflammatory diseases of the oral cavity, a number of herbal preparations are used (tincture of calendula, tincture of eucalyptus, chlorophyllipt, salvin, novoimanin, sanguirithrin), extracts of St. John's wort, chamomile flowers, decoction of oak bark, rhizomes and roots of Potentilla, complex remedies, maraslavin, rotocan and others [Mashkovsky M.D. Medicines. In 2 volumes. T. 1. - 14th ed., Revised, revised. and add. - M .: LLC "New Wave Publishing House": Publisher Divov, 2002. - 540 p.].

However, these funds are not effective enough: they do not take into account the complex nature of the pathogenesis of inflammatory diseases of the oral cavity. In addition, these drugs do not differ in the variety of groups of biologically active substances (BAS); the monopreparations used cannot contain a complex of biologically active substances of various groups, often present in a plant object, due to the extraction selectivity of the extractant. In addition, complex preparations often include extracts from plants that accumulate the same or similar groups of active substances, which narrows the spectrum of their pharmacological action.

Known "Dental phytofilms for the treatment of inflammatory diseases of the periodontal and oral mucosa" containing as active substances sanguirithrin, oil extract of flowers of calendula and herb yarrow in a ratio of 1: 1 and dry extract of echinacea, as a film former and plasticizer contains, respectively, hydroxyethyl cellulose and glycerol , contains Cremophor RH-40, sodium saccharinate, mint oil and purified water as auxiliary substances (RU 2618392 dated 05/03/2017).

However, the composition of the phytofilm containing sanguirithrin presented above has some disadvantages. Sanguirithrin has a wide spectrum of antimicrobial activity, acting on gram-positive and gram-negative bacteria, yeast-like and filamentous fungi, pathogenic protozoa, incl. multidrug-resistant strains of microorganisms. However, long-term use of this composition leads to a change in the microbial "landscape" in the oral cavity. In addition, the oil extract of the yarrow herb, which is part of the proposed composition, contains a complex of alkaloids: stachydrin, achillein, betonitsin, etc., which, in turn, can lead to undesirable side effects.

Also known is the composition of the ointment, including 40% alcohol tincture of the herb of resin drooping or rhizomes with roots of leuzea, flowers of medicinal marigolds, meadowsweet grass, taken in mass parts 3: 1: 1, petroleum jelly, anhydrous lanolin, taken in mass parts 3: 2, essential oil of clove and eucalyptus for the treatment of traumatic lesions of the oral cavity in the process of orthodontic treatment, presented in the patent of the Russian Federation "Method for the treatment of traumatic lesions of the oral mucosa in the process of orthodontic treatment" (RU 2577240 from 10.03.2016).

The disadvantage of this agent is the possibility of cell dehydration and coagulation of the cellular protoplasm during prolonged contact with the oral mucosa.

The composition of a film with an anti-inflammatory effect is known: an extract of lanceolate cocoa leaves, a mixture of Tween 80-dimethylsulfoxide-glycerin in a ratio of 1: 1: 10, a 5% solution of carboxymethylcellulose in a ratio of 1: 5 and a 10% solution of gelatin (RU 2395292 from 27.07.2010) ...

However, a significant disadvantage of the proposed composition is the presence of dimethyl sulfoxide, which, after being applied to the skin and mucous membranes, can contribute to the development of local side effects in the form of rashes, itching, and burning. Its use can cause the development of systemic side effects, which with a predisposition to allergic diseases can develop bronchospasm.

It should be noted that one of the fairly effective methods of treatment and prevention of diseases of the oral cavity is peloid therapy.

On the pharmaceutical market, there is an anti-periodontal toothpaste based on Baldonskaya therapeutic mud, which includes: Baldonskaya therapeutic mud, calcium carbonate, silicium dioxide, sorbitol, cecol 2000, empicol, sodium fluoride, antioxidants, metronidazole, furagin (https: // www.krasotta.ru/bl_zb_pasta.php).

However, this agent can only be considered as a prophylactic one, since the presented composition will not be able to provide a long-term therapeutic effect, since it must be quickly removed from the oral cavity. The use of sodium fluoride, which is one of the leading components of the presented composition, can significantly inhibit the formation of new bone tissue; the structure of already existing bones becomes porous and brittle, as a result of which a fluorotic lesion of the enamel develops and as a result the teeth are destroyed.

A patent search showed that there is no complete analogue of the proposed dental film containing dried aqueous extracts of astragalus fox and an aqueous extract of sulfide-silt iodine-bromine therapeutic mud used for the treatment and prevention of alveolitis.

The closest analogue - the prototype of the claimed agent is "Dental phytofilms for the treatment of traumatic lesions of the oral mucosa during orthodontic treatment" (RU 2651706 dated 04.23.2018), intended for the treatment and prevention of traumatic lesions of the oral mucosa during orthodontic treatment and the composition of the following components: extracts of calendula flowers and yarrow herb in a ratio of 1: 1, 10% propolis tincture, gelatin, glycerin and purified water.

However, the extract of the yarrow herb, which is part of the proposed composition, contains a complex of alkaloids: stachydrine, achillein, betonitsin, etc., which can lead to undesirable side effects: allergic reactions, nausea, dizziness, etc. In addition, the contained alkaloid - achillein is contraindicated for individuals with increased blood clotting. In addition, the composition of the proposed drug includes propolis tincture, which has a number of side effects: allergic reactions, dry mouth, dizziness, etc.

Taking into account the polyetiology of diseases of the tissues and mucous membranes of the oral cavity, such requirements as anti-inflammatory, antibacterial activity, the ability to improve blood circulation and enhance tissue regeneration are imposed on dental drugs.

Accordingly, the main object of the invention is to expand the range of dental agents in the form of an application agent for the treatment and prevention of inflammatory diseases of the oral cavity during surgery.

The technical result is to obtain a new drug of domestic production in the form of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition, which has a prolonged, antimicrobial (gram-positive and gram-negative bacteria, yeast-like and filamentous fungi, pathogenic protozoa, including multi-resistant strains of microorganisms) anti-inflammatory, immunomodulatory, regenerating, hemostatic action, with good fixation, convenient and hygienic to use.

The specified technical result is achieved by the fact that the agent for the treatment and prevention of alveolitis contains, as active ingredients, a dried aqueous extract of fox astragalus and an aqueous extract of sulfide-silt iodine-bromine mud, gelatin, glycerin, lidocaine hydrochloride, ascorbic acid, nipagin, sorbitol sweetener, essential oil peppermint and purified water.

In the available sources of scientific, technical and patent literature, information about the agent in the form of a dental film for the treatment and prevention of alveolitis, which developed after extirpation of the tooth, and containing a dried aqueous extract of fox astragalus and an aqueous extract of sulfide-silt iodine-bromine mud as an active ingredient, was not found. ... Thus, the claimed invention meets the "novelty" criterion.

When checking the patentability of the claimed invention, it was found that it corresponded to the conditions of industrial applicability, since the high quality of the obtained product and the expansion of the range of application of the funds created on the basis of the above extracts were achieved.

The inventive agent is made in the form of a soft dosage form - a film, which has many advantages over other dental dosage forms: they can be used to regulate the kinetics of release of active components, prolong the therapeutic effect, combine medicinal substances belonging to various pharmacotherapeutic and physical - chemical groups. Along with this, the dental film can be independently applied by the patient and, if necessary, can be easily removed from the application site, convenient and safe to use.

The composition of the film base includes available ingredients that can provide the entire range of the claimed pharmacological effects.

The unique chemical composition of astragalus fox determines the breadth of its biological effects on the body. In folk medicine, infusions of astragalus fox are used in the form of lotions for various wounds of the skin, as well as in the form of rinsing for diseases of the oral mucosa. It is known that the aqueous extract of astragalus fox has a pronounced wound-healing, membrane-stabilizing, antioxidant and immunomodulatory activity, as well as the ability to restore biological substrates, promote an increase in the activity of glutathione peroxidase, pyruvate kinase and catalase, exhibit a pronounced antiradical effect and inhibit the process of degradation.

The constituents of peppermint essential oil are capable of having an anti-inflammatory, antispasmodic, antiseptic effect, while exerting a bactericidal effect on representatives of the pathogenic flora of the oral cavity, including some types of fungus.

Sulfide-silt iodine-bromine mud has an active biological effect on the mucous membrane of the oral cavity. The use of mud does not always justify its use, so in particular, it is unacceptable to use mud on the mucous membrane of the oral cavity. However, the application of the mud extract is more convenient. The extract of therapeutic mud has a similar chemical composition as the native mud, and, therefore, provides the same pharmacological effects, namely: it provides vasodilation, increases lymph and blood flow. Mineral and biologically active substances of the mud help to enhance cell metabolism and regenerative processes in tissues.

Due to the activation of blood circulation and metabolism in the mucous membrane, cells receive more oxygen and nutrients, which means that the processes of cellular renewal take place more intensively. Salts, which are rich in composition, have an osmotic active effect. In addition, the mineral salts contained in the mud extract have a remineralizing effect, enhancing the mineralization processes in hard tissues.

As a film base gelatin is used with the addition of glycerin (RU 2147874 dated 04/27/2000 "Composition of the base for medicinal films"). Such a basis ensures the duration of the action of medicinal substances. Gelatin, upon contact with a wet surface, exhibits an adhesive (sticking) effect and the dosage form is firmly fixed in a given area. Such contact provides targeted (targeted) delivery of medicinal substances to the pathology zone or a nearby area and allows achieving a therapeutic effect in doses of 1/10 or 1/20 of the average therapeutic dose. The high viscosity of gelatin promotes long-term drug release. The hemostatic and reparative properties of gelatin also play a positive role.

Lidocaine hydrochloride in dental medicines when applied topically in the form of gels, sprays at a concentration of 2 to 4% is sufficient to relieve pain without developing a systemic effect. The tool has high efficiency, safety and fast action. The maximum duration of the analgesic effect can be up to 1 hour.

Additional administration of ascorbic acid (vitamin C) helps to optimize collagen synthesis, as a result, stronger callogenic fibers are formed, which leads to a decrease in the fragility of the walls of blood vessels, a decrease in the fragility of bones, bone septa, and the structure of dentin is restored. Vitamin is able to enhance the phagocytic activity of leukocytes and improve tissue regeneration.

The use of the selected auxiliary components determines the positive technological characteristics and the pharmacological synergy of all ingredients used in the composition of the product.

Sorbitol is used as a flavoring agent and emulsifier, which, along with the listed properties, has additional positive qualities. In particular, when introduced into the composition of external soft forms, including toothpaste, it prevents its rapid drying, due to the hygroscopicity of sorbitol. Due to this property of sorbitol, soft forms retain the desired consistency for a long time. Of great importance is the fact that sorbitol plays the role of an anti-carious component. Caries prevention is achieved through the ability to inhibit the production of bacteria in the oral cavity. Sorbitol is able to normalize the acidity of saliva to pH 7 and thereby block the processes of enamel demineralization.

Nipagin is recognized as a safe preservative and is approved for use in the manufacture of pharmaceuticals, cosmetics, food supplements and other therapeutic products. Nipagin acts as an antiseptic and preservative. It shows the greatest activity in relation to gram-positive bacteria (staphylococci, streptococci, actinomycetes, listeria), suppressing their vital activity. When in contact with mucous membranes, it causes a local anesthetic effect.

The claimed agent in the form of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition containing, as active ingredients, a dried aqueous extract of fox astragalus, peppermint essential oil, an aqueous extract of sulfide-silt iodine-bromine mud therapeutic, gelatin, glycerin, lidocaine hydrochloride, ascorbic acid nipagin, sorbitol sweetener and purified water, is applied in the form of an application in the pathological zone or in the maximum proximity to it 1-3 times a day.

The claimed agent in the form of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition can be prepared as follows: a precisely weighed amount of gelatin dissolves in purified water and remains for some time to swell, after which a certain amount of glycerin (film base) is introduced; dried aqueous extract of fox astragalus, obtained by vortex extraction with purified crushed raw materials in a ratio of 1: 1, followed by distillation of the extractant and drying to a residual moisture content of no more than 5%, is dissolved in purified water, in which ascorbic acid, chlorhexidine bigluconate, lidocaine hydrochloride are previously dissolved and introduced an aqueous extract of sulfide-silt iodine-bromine therapeutic mud, obtained by diluting it with purified water in a ratio of 1: 3, followed by centrifugation; after which the resulting combined mixture is combined with a film base with constant stirring and until a homogeneous mass is obtained; then nipagin is introduced into the resulting mass. The resulting film mass is formed by pouring onto special substrates, followed by drying to the optimal residual moisture. Finished films are removed from the substrates and cut to the required size.

Means in the form of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition, containing as active ingredients dried aqueous extract of fox astragalus, peppermint essential oil, aqueous extract of sulfide-silt iodine-bromine therapeutic mud, gelatin, glycerin, lidocaine hydrochloride, ascorigonohexidine acid, nipagin, sorbitol sweetener and purified water were evaluated based on technological, microbiological and biopharmaceutical criteria.

The technical result of the invention is to improve the technological and biopharmaceutical properties of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition, including appearance, color, odor, average weight, weight loss on drying, pH value, thermal stability, ability to lag behind the substrate surface, dissolution time, absence of microcracks, fixation, shelf life.

The essence of the claimed invention is illustrated by the following examples showing the achievement of the technical result.

Example 1. Dental film for the treatment and prevention of alveolitis with a phytopeloid composition containing a dried aqueous extract of astragalus fox 8.0 wt. %, peppermint essential oil 0.1 wt. %, aqueous extract of sulphide-silt iodine-bromine therapeutic mud 2.0 wt. %, gelatin 8.0 wt. %, glycerin 3.0 wt. %, lidocaine hydrochloride 3.0 wt. %, chlorhexidine bigluconate 3.0 wt. %, ascorbic acid 2.0 wt. %, nipagin 0.3 wt. %, sweetener sorbitol 3.0 wt. % and purified water - the rest.

The resulting dental film for the treatment and prevention of alveolitis with a phytopeloid composition was a light yellow, homogeneous polymer plate, without mechanical impurities, with a menthol smell, sweetish taste, pH within 6.6-6.7, thermostable, average weight 0.041 ± 0.003 g, loss in weight on drying did not exceed 14%, with poor fixation, easily lagged behind the surface of the substrate, with no microcracks, dissolution time 10 ± 5 min, shelf life was 18 months.

Example 2. Dental film for the treatment and prevention of alveolitis with a phytopeloid composition containing a dried aqueous extract of fox astragalus 10.0 wt. %, peppermint essential oil 0.1 wt. %, an aqueous extract of sulfide-silt iodine-bromine therapeutic mud 3.0 wt. %, gelatin 10.0 wt. %, glycerin 5.0 wt. %, lidocaine hydrochloride 4.0 wt. %, chlorhexidine bigluconate 4.0 wt. %, ascorbic acid 3.0 wt. %, nipagin 0.5 wt. %, sweetener sorbitol 4.0 wt. %, and purified water - the rest.

The resulting dental film for the treatment and prevention of alveoitis with a phytopeloid composition was a light yellow, homogeneous, elastic polymer plate, without mechanical impurities, with the smell of menthol, sweetish taste, pH within 6.8-6.9, thermostable, average weight 0.035 ± 0.003 g, loss in weight on drying did not exceed 14%, with good fixation, easily lagged behind the substrate surface, with no microcracks, dissolution time 15 ± 5 min, shelf life was 24 months.

Example 3. The time of dissolution and release of a complex of active components from a dental film for the treatment and prevention of alveolitis with a phytopeloid composition according to examples No. 1 and No. 2 was studied by diffusion into an agar gel, in which a solution of iron (III) chloride was introduced.

The degree of release was judged by the diameter of the colored zones, which was measured after 3, 5, 7, 10, 13, 15 and 20 minutes. The results of the study are presented in table 1 "Results of studying the time and release of the complex of active components from the dental film for the treatment and prevention of alveolitis with phytopeloid composition according to examples No. 1 and No. 2".

The results presented in Table 1 allow us to conclude that the release of active components from the dental film for the treatment and prevention of alveolitis with the phytopeloid composition according to examples No. 1 and No. 2 begins 5 minutes after the beginning of the experiment and reaches the maximum yield when they are completely dissolved. In addition, a fairly rapid dissolution of the film and the release of the complex of active components from the film is provided by the base presented in example No. 1 (10 min ± 5 min.).

The intensity of the kinetics of the release of the complex of active components from the base of the dental film for the treatment and prevention of alveolitis with a phytopeloid composition according to example No. 2 indicates a more prolonged effect of the developed composition (15 min ± 5 min).

Example 4. The developed dental film for the treatment and prevention of alveolitis with a phytopeloid composition according to examples No. 1 and No. 2 was tested for microbiological purity to control the microbial contamination of the proposed samples. For the cultivation of bacteria, casein soybean agar was used, for yeast and mold fungi, Sabouraud agar with glucose was used. For each laboratory sample of films, at least 5 Petri dishes were used. The crops were examined daily. Colonies are counted after 48 - 72 hours (preliminary result) and after 5 days (final result). Preliminarily, the films were dispersed in a physical solution of sodium chloride 0.9%, and several dilutions of the samples were prepared.

The number of microorganisms (N) in 1.0 g of the film was calculated using the formula:

N = Σ c / n d 10, where:

с - the number of colonies on all Petri dishes;

n is the number of Petri dishes;

d is the dilution factor of the sample;

10 - conversion factor when seeding per cup in a volume of 0.1 ml.

The results showed that on Petri dishes with casein-soybean agar when inoculating dispersed dental film for the treatment and prevention of alveolitis with phytopeloid composition according to example No. 2 at a dilution of 1:10, there was no growth of bacteria, when inoculating a dispersed film of sample No. 1 at a dilution of 1: 100 there was also no bacterial growth, but single colonies of microorganisms were observed when plated at a dilution of 1:10.

Thus, it can be noted that 1.0 g of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition according to example No. 2 contains less than 10 bacteria, and 1.0 g of a film according to example No. 1 contains less than 100 bacteria.

On Petri dishes with Sabouraud agar, when plating dispersed films of all samples at a dilution of 1:10, single colonies of Aspergillus niger were observed.

Thus, it can be noted that 1.0 g of dental film for the treatment and prevention of alveolitis with the phytopeloid composition according to examples No. 1 and No. 2 contains less than 10 mold spores.

Thus, the results obtained indicate 99.0% microbiological purity of laboratory samples of dental film for the treatment and prevention of alveolitis with phytopeloid composition according to examples No. 1 and No. 2.

The antibacterial and antifungal activity of the proposed examples of dental films for the treatment and prevention of alveolitis with a phytopeloid composition was evaluated by the diffuse-well method. The experiment used strains of Lactobacillus casei, Lactobacillus acidophilus, Staphylococcus aureus, Staphylococcus saprophiticus, Streptococcus salivarius ,, Candida albicans, which inhabit the oral cavity at different periods of human life and are capable of causing infectious and inflammatory processes.

Method of microbiological research: cultures of test microorganisms were grown for 6 hours at 37 ° C in sugar broth. The initial inoculation dose was 10 ⁷ microbial cells of daily agar culture. Next, 0.1 ml of broth culture was introduced into 1 ml of the studied dispersed dental film for the treatment and prevention of alveolitis with a phytopeloid composition and in parallel in 1 ml of a 0.9% physical solution (control).

The contact time of test cultures of microorganisms with dispersed dental film for the treatment and prevention of alveolitis with the phytopeloid composition and control was 3, 6, 12 and 24 hours. At the end of the contact time of microorganisms with the dispersed dental film for the treatment and prevention of alveolitis with the phytopeloid composition and control, inoculations of 0.1 ml of solution were carried out on the surface of mesopatamia agar in the form of a continuous lawn. Crops were incubated in a thermostat at 37 ° C for 24 hours.

The results of suppression of the growth of test cultures of microorganisms developed examples of dental film for the treatment and prevention of alveolitis with phytopeloid composition No. 1 and No. 2 are presented in Table 2 "Suppression of the growth of test cultures of microorganisms developed examples of dental film for treatment and prevention of alveolitis with phytopeloid composition No. 1 and No. 2 ".

The results of the study of a dental film for the treatment and prevention of alveolitis with a phytopeloid composition according to example No. 2 showed that the developed compositions of this film have more pronounced antibacterial and antifungal effects compared to a dental film for the treatment and prevention of alveolitis with a phytopeloid composition according to example No. 1.

After 3 hours of exposure of the dispersed dental film for the treatment and prevention of alveolitis with phytopeloid composition No. 2 with suspensions of microorganisms, the smallest number of colonies was observed in comparison with the first sample of the film. 24 hours after contact with suspensions of microorganisms and subsequent inoculation on mesopatamia agar, single colonies of all test cultures of microorganisms were observed.

The conducted microbiological studies show that the dental film for the treatment and prevention of alveolitis with a phytopeloid composition according to example No. 2 has 95.5% antibacterial and antifungal activity against gram-positive cocci, gram-positive non-spore-forming rods, gram-negative bacteria, yeast fungi related to opportunistic microorganisms and participating in the pathological processes of the oral cavity.

Thus, a dental film for the treatment and prevention of alveolitis with a phytopeloid composition is convenient and hygienic to use, with good fixation and prolonged effect, as well as having antimicrobial and antibacterial actions.

Claims (2)

Dental film for the treatment and prevention of alveolitis with a phytopeloid composition based on a plant extract, characterized in that it contains a dried aqueous extract of astragalus fox, peppermint essential oil, an aqueous extract of sulfide-silt iodine-bromine therapeutic mud, gelatin, glycerin, lidocaine hydrochloride, ascorbic acids, ascorbic acid nipagin, sorbitol sweetener and purified water in the following ratio of components, wt%: Dried Aqueous Extract of Astragalus Fox 8.0-10.0 Peppermint essential oil 0.05-0.1 Aqueous extract of sulfide-silt iodine-bromine 2.0-3.0 healing mud Gelatin 8.0-10.0 Glycerol 3.0-5.0 Lidocaine hydrochloride 3.0-4.0 Vitamin C 2.0-3.0 Nipagin 0.3-0.5 Sorbitol 3.0-4.0 Purified water rest